• Thomas H Massey and Duncan J McLauchlan.
• University Hospital of Wales, Cardiff & Vale University Health Board, Cardiff, UK; Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, UK; UK Dementia Research Institute at Cardiff University, Cardiff, UK. Electronic address: MasseyT1@cardiff.ac.uk.
• Clin Med (Lond). 2024 Mar 1; 24 (2): 100200100200.

AbstractHuntington's disease (HD) usually manifests in adulthood and is characterised by progressive neurodegeneration in the brain that causes worsening involuntary movements, mental health and cognition over many years. Depression, anxiety and apathy are common. HD is autosomal dominant and affects about 1 in 8,000 people in the UK. There are currently no disease-modifying treatments and so patient care centres on multidisciplinary therapy support and medical treatments to relieve distressing symptoms. Progression of HD is usually slow, and so acute deteriorations often indicate another problem, such as intercurrent infections, constipation, urinary retention, gastro-oesophageal reflux disease or poor dentition. In this review we outline common presentations in HD patients, both acute and chronic, consider therapeutic options and discuss specific considerations in advanced HD.Copyright © 2024. Published by Elsevier Ltd.

12 keywords...

hide…